Ipsen's Dysport Becomes First Botulinum Toxin To Show Statistically Significant Efficacy In Episodic Migraine, Positioning It As Potential First-In-Class Treatment

IPSEN SA

IPSEN SA

IPSEY

0.00
  • Dysport achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraine
  • Dysport is the first botulinum toxin in episodic migraine to demonstrate a statistically significant reduction in monthly migraine days
  • Dysport was well-tolerated across both trials with safety consistent with the known profile
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.